XPrize Launches Competition to Develop Anti-Aging Drugs
Photo: MIT Technology Review
Quick answer
XPrize’s $101 million competition aims to develop anti-aging drugs that reverse biological age by 10+ years in a year. Participants must prove improvements in immunity, cognition, and muscle function.
The XPrize Foundation has launched an ambitious $101 million competition aimed at developing anti-aging technologies. Participants must prove the effectiveness of their methods by reversing human biological age by 10 or more years within a single year of treatment. Key indicators will include improvements in immune function, cognitive abilities, and muscle performance.
Leading the trials is David Sinclair, a biologist from Harvard Medical School. He plans to test a combination of oral drugs on volunteers, based on cellular chemical reprogramming. This approach could be revolutionary in the fight against aging, opening new possibilities for extending healthy lifespans.
The XPrize competition is attracting attention not only from scientists but also from investors, as successful developments in this field could transform medicine and biotechnology. The trial results are expected to mark a significant step toward creating effective anti-aging therapies.
Common questions
- What are the winning criteria for the XPrize anti-aging competition?
- Teams must demonstrate a reversal of biological age by 10+ years within a year of treatment, with measurable improvements in immune function, cognitive abilities, and muscle mass.
- Who is involved in the anti-aging drug trials?
- Harvard biologist David Sinclair will test a combination of oral drugs based on cellular chemical reprogramming on volunteers.
- What are the future prospects for anti-aging research?
- Successful breakthroughs could revolutionize treatments for age-related diseases and significantly extend healthy lifespans, positioning anti-aging as a key focus in biotechnology.
Dzen feed: /feed/dzen.xml · RSS: /feed.xml